HG004 is a one-time, direct-to-RPE treatment of inherited retinal disease caused by mutations in the RPE65 gene ~10-fold lower vector doses in multiregion, multicenter HG00402 trial than other AAV2 gene therapy clinical trials HG004 was previously granted orphan drug designation (ODD) for…